phenylcapsaicin
/ aXichem
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
January 23, 2025
CROSSCAPS: Effect of Acute Phenylcapsaicin Intake on Trained Cross-Training Athletes
(clinicaltrials.gov)
- P=N/A | N=50 | Active, not recruiting | Sponsor: Universidad de Granada
New trial
June 26, 2024
Effects of Phenylcapsaicin on Intraocular and Ocular Perfusion Pressure During a 30-Min Cycling Task: A Placebo-Controlled, Triple-Blind, Balanced Crossover Study.
(PubMed, Int J Sport Nutr Exerc Metab)
- "These findings suggest that PC intake before exercise should be avoided when reducing IOP levels is desired (e.g., glaucoma patients or those at risk). Future studies should determine the effects of different ergogenic aids on IOP and OPP levels with other exercise configurations and in the long term."
Journal • Glaucoma • Infectious Disease • Ophthalmology
December 15, 2023
Safety and efficacy of a feed additive consisting of phenylcapsaicin (aXiphen) for chickens for fattening (aXichem AB).
(PubMed, EFSA J)
- "It is unlikely that phenylcapsaicin bioaccumulates in the environment and the risk of secondary poisoning is considered low. The FEEDAP Panel could not conclude on the efficacy of the additive in chickens for fattening at the proposed conditions of use."
Journal
August 21, 2023
Effects of different phenylcapsaicin doses on neuromuscular activity and mechanical performance in trained male subjects: a randomized, triple-blinded, crossover, placebo-controlled trial.
(PubMed, Front Physiol)
- "Intra-set analyses revealed higher velocities in HD compared to those in LD (p = 0.01) and PLA (p range = 0.004-0.008). Therefore, PC may improve the strength performance and attenuate the mechanical fatigue induced by resistance training in SQ and CMJ exercises."
Journal • Fatigue
August 01, 2023
MELFENIL: Oral Bioavailability of Two Melatonin Supplements
(clinicaltrials.gov)
- P=N/A | N=12 | Completed | Sponsor: Fundació Eurecat | Recruiting ➔ Completed
Trial completion
June 06, 2023
MELFENIL: Oral Bioavailability of Two Melatonin Supplements
(clinicaltrials.gov)
- P=N/A | N=12 | Recruiting | Sponsor: Fundació Eurecat | Not yet recruiting ➔ Recruiting
Enrollment open
May 25, 2023
Effects of phenylcapsaicin on aerobic capacity and physiological parameters in active young males: a randomized, triple-blinded, placebo-controlled, crossover trial.
(PubMed, Front Physiol)
- "In the incremental test, only general RPE at 60% of the maximal intensity (W) differed favoring HD (p ≤ 0.05). Therefore, PC may contribute to increase aerobic capacity through the improvement of fat oxidation, maximum heart rate and perceptual responses during exercise."
Journal
May 08, 2023
"aXichem presenterar aXivite och kraften i phenylcapsaicin vid Vitafoods Europe 2023, tillsammans med sina partners BART och Pharmafoods https://t.co/ER6U0O8G0S"
(@CisionNews)
April 28, 2023
MELFENIL: Oral Bioavailability of Two Melatonin Supplements
(clinicaltrials.gov)
- P=N/A | N=12 | Not yet recruiting | Sponsor: Fundació Eurecat
New trial
April 26, 2023
Effects of different phenylcapsaicin doses on resistance training performance, muscle damage, protein breakdown, metabolic response, ratings of perceived exertion, and recovery: a randomized, triple-blinded, placebo-controlled, crossover trial.
(PubMed, J Int Soc Sports Nutr)
- "This study suggests that PC may favorably influence SQ performance, RPE-AM, and muscle damage compared to PLA. However, HD exhibited most of the biochemical and mechanical anti-fatigue effects instead of LD."
Clinical • Journal • Fatigue
October 27, 2022
aXichem obtains patent for phenylcapsaicin for use in the treatment of idiopathic pulmonary fibrosis [Google translation]
(Cision)
- "aXichem AB (publ) , which develops and markets natural analogue industrial chemicals , announces that the company has received patent protection for the company's unique product, phenylcapsaicin, for use in the treatment of idiopathic pulmonary fibrosis ( IPF )."
Patent
1 to 11
Of
11
Go to page
1